We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NXPI:NASDAQNXP Semiconductors N.V. Analysis

Data as of 2026-04-21 - not real-time

$225.15

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

NXP Semiconductors trades near $225, well above its DCF fair value of $101, indicating the market is pricing in strong growth expectations. The stock shows an overbought RSI of 71 and a bullish MACD histogram, while the computed trend remains bearish, suggesting short‑term price pressure. Revenue is growing at 7.2% YoY with a healthy gross margin of 55% and operating margin of 26%, and forward earnings are projected to double (forward EPS $16.70 vs trailing $7.95), compressing the forward PE to 13 versus a trailing PE of 28. The dividend yield of 1.83% is supported by a 51% payout ratio and solid operating cash flow, but the balance sheet is leveraged (debt‑to‑equity 120% and total debt $12.5 B). Analyst consensus remains bullish with a median price target of $257, implying ~15% upside, yet the high beta of 1.68 and 30% 30‑day volatility underscore market sensitivity. Extreme Greed sentiment (fear‑greed index 86) further fuels price enthusiasm. Overall, the stock appears overvalued on a DCF basis but carries compelling growth catalysts and a sustainable dividend, balanced against cyclical sector risk and elevated leverage.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • RSI overbought at 71
  • Computed bearish trend direction
  • Current price far above DCF fair value

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Revenue growth of 7.2% and expanding margins
  • Forward EPS upside and forward PE of 13
  • Analyst median target of $257 indicating ~15% upside

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Secular demand in automotive and IoT markets
  • High leverage (debt‑to‑equity 120%)
  • Sustainable dividend with 51% payout ratio

Key Metrics & Analysis

Financial Health

Revenue Growth7.20%
Profit Margin16.47%
P/E Ratio28.3
ROE20.70%
ROA8.01%
Debt/Equity119.71
P/B Ratio5.7
Op. Cash Flow$2.8B
Free Cash Flow$1.9B
Industry P/E36.9

Technical Analysis

TrendBearish
RSI70.8
Support$184.68
Resistance$226.49
MA 20$203.35
MA 50$211.81
MA 200$219.21
MACDBullish
VolumeStable
Fear & Greed Index86.14

Valuation

Fair Value$101.26
Target Price$258.68
Upside/Downside14.89%
GradeOvervalued
TypeGrowth
Dividend Yield1.83%

Risk Assessment

Beta1.68
Volatility30.46%
Sector RiskHigh
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.